Stanley-Laman Group
CORT icon

Stanley-Laman Group’s Corcept Therapeutics CORT Stock Holding History

Stanley-Laman Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.65M Sell
66,365
-1,831
-3% -$197K 0.84% 29
2026
Q2 		$5.93M Sell
68,196
-429
-0.6% -$25.9K 0.6% 43
2026
Q1 		$2.77M Buy
68,625
+35,314
+106% +$1.32M 0.34% 110
2025
Q4 		$1.16M Buy
33,311
+8,828
+36% +$693K 0.15% 159
2025
Q3 		$2.03M Buy
+24,483
New +$1.77M 0.29% 126

Other funds holding CORT

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Linden Thomas Advisory Services
Linden Thomas Advisory Services Charlotte, North Carolina $1.26B AUM 37.95% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Quadrant Capital Group
Quadrant Capital Group Cincinnati, Ohio $3.7B AUM 33.76% 1-Year Est. Return
Vilga Financial Planning
Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return
Burney Company
Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Stanley-Laman Group's CORT Position: Q3 2026 in Review

Stanley-Laman Group reduced its Corcept Therapeutics (CORT) stake by 2.7% in Q3 2026, selling an estimated $197K and leaving 66,365 shares worth $7.65M. The position accounts for 0.84% of the portfolio, ranked #29.

Stanley-Laman Group first reported a position in CORT in Q3 2025 and has held it in 5 quarters since. 52 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Stanley-Laman Group held 66,365 shares of Corcept Therapeutics worth $7.65M as of Q3 2026.
  • Stanley-Laman Group sold 1,831 Corcept Therapeutics shares in Q3 2026, an estimated $197K.
  • Corcept Therapeutics made up 0.84% of Stanley-Laman Group's portfolio in Q3 2026, its #29 holding.
  • Stanley-Laman Group first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 52 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Stanley-Laman Group's 13F filing for Q3 2026, filed 20 Oct 2026.